FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	
---	--

(				ection 30(h) of the Inv					,			•
Name and Address of Reporting Person* <u>Cohen Chad M</u>				2. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ ADPT ]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify			
(Last)	(First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)					below)	below)		
C/O ADAPTI	VE BIOTECHI	NOLOGIES COR	$^{1}$ P. $^{08/1}$	7/2020						Chief Fina	ncial Officer	
SUITE 200												
-			4. If A	mendment, Date of 0	Original	Filed	(Month/Day/Ye	ar)	6. Indi Line)	vidual or Joint/Group	Filing (Check A	pplicable
(Street)									X	Form filed by One	Reporting Pers	on
SEATTLE	WA	98102								Form filed by More than One Reporting Person		
(City)	(State)	(Zip)										
		Table I - Nor	n-Derivative	Securities Acqu	uired,	Disp	osed of, o	r Ben	eficially	Owned		
Date			2. Transaction Date (Month/Day/Yea	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)  4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of 6. Date Exercisable and 8. Price of 9. Number of 11. Nature 3. Transaction 3A. Deemed 5. Number 7. Title and Amount 10. of Securities Underlying Derivative Security Conversion Date (Month/Day/Year) Execution Date, Transaction Expiration Date (Month/Day/Year) derivative Securities Ownership of Indirect Beneficial of Derivative Security (Instr. 5) Security (Instr. 3) or Exercise Code (Instr. 8) if any (Month/Day/Year) Form: Price of Derivative Security Direct (D) Securities Beneficially Ownership Acquired (A) or Owned Following or Indirect (I) (Instr. 4) (Instr. 3 and 4) (Instr. 4) Reported Transaction(s) Disposed of (D) (Instr 3, 4 and 5) (Instr. 4) Amount or Number Date Expiration Date Code (A) (D) Exercisable Title Shares Stock Option \$6.32 08/17/2020 $M^{(1)}$ 10,000 (2) 08/25/2025 10,000 \$0.00 610,000 D (Right To Stock

 $M^{(1)}$ 

S(1)

10,000

10,000

A

D

\$6.32

\$40

11,000

1,000

D

D

## **Explanation of Responses:**

Common Stock

Common Stock

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019.

08/17/2020

08/17/2020

2. The option is fully vested and exercisable.

## Remarks:

/s/ Chad Cohen by Eric Billings, Attorney-in-Fact

08/19/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.